Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products > 106650 > 


Products Categories

Basic Information
CAS No.: 106650-56-0
Name: Sibutramine
Article Data: 18
Cas Database
Molecular Structure:
Molecular Structure of 106650-56-0 (Sibutramine)
Formula: C17H26ClN
Molecular Weight: 279.853
Synonyms: UNII-WV5EC51866;Didemethylsibutramine hydrochloride;Medaria;Racemic sibutramine;
Density: 1.031 g/cm3
Melting Point: 191-192 °C
Boiling Point: 342.6 °C at 760 mmHg
Flash Point: 161 °C
Solubility: Water solubility: 2.9 mg/mL
Appearance: Yellowish solid
Transport Information: 25kgs
PSA: 3.24000
LogP: 4.73800
Downstream Products
  • Display:default sort

    New supplier

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.


Molecular Structure:

Molecular Formula: C17H26ClN
Molecular Weight: 279.848
IUPAC Name: 1-[1-(4-Chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
Synonyms of Sibutramine (CAS NO.106650-56-0): Sibutramine [INN:BAN] ; Medaria ; Reductil ; Sibutramina ; Sibutramina [Spanish] ; Sibutraminum ; Sibutraminum [Latin] ; UNII-WV5EC51866 ; Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)- ; DEA No. 1675
CAS NO: 106650-56-0
Classification Code: Anti-Obesity Agents ; Antidepressive agents ; Appetite depressants ; Central Nervous System Agents ; Psychotropic Drugs
Melting point: 191-192°C 
Index of Refraction: 1.529
Molar Refractivity: 83.76 cm3
Molar Volume: 271.3 cm3
Surface Tension: 37.3 dyne/cm
Density: 1.031 g/cm3
Flash Point: 161 °C
Enthalpy of Vaporization: 58.64 kJ/mol
Boiling Point: 342.6 °C at 760 mmHg
Vapour Pressure: 7.45E-05 mmHg at 25°C


 Sibutramine (CAS NO.106650-56-0) has been used as an appetite suppressant administered orally for the treatment of obesity.


  Sibutramine (CAS NO.106650-56-0) is a centrally-acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines, and is also under review by the FDA and the European Medicines Agency. It is classified as a Schedule IV controlled substance in the United States, despite having virtually no potential for misuse due to its lack of appreciable dopaminergic effects. As a neurotransmitter reuptake inhibitor, it reduces the reuptake of serotonin (by 53%), norepinephrine (by 54%), and dopamine (by 16%), thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety. It has a number of clinically significant interactions, and a higher number of cardiovascular events has been observed in people taking it verses control (11.4% vs. 10.0%).